In what promises to be a further casting of the ABS net, Global Asset Capital said it is currently engaged in structuring a credit facility secured by royalty revenues on a well known new drug.

While declining to provide specifics, Rana Mookherjee, one of Global Asset's officers, said the securitization will be $25 million to $30 million in size and have a term of approximately seven-years, which would conform to the patent protected life cycle of the drug.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.